close

Join our Mailing List

Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.

Tag
Centre For Probe Development And Commercialization
Mar 25, 2024
OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion
OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion
Sep 14, 2022
<strong>New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals</strong>
New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals
Aug 02, 2018
Ontario centre attracts national attention for probe research, development and commercialization
Ontario centre attracts national attention for probe research, development and commercialization
Oct 04, 2017
FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
Feb 23, 2017
FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
Oct 05, 2016
From our Annual Report: Investing in the cure and the economy
From our Annual Report: Investing in the cure and the economy
Mar 16, 2016
FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic
FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic
Dec 16, 2015
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
Looking Ahead
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
Subscribe